Access Treatment and Support for CABLIVI

Getting started with CABLIVI

HemAssist works with you and your patients to get them started CABLIVI as efficiently as possible. Our support begins with the enrollment process. As soon as we receive an enrollment form, we can begin a benefits investigation to determine if your patient is eligible for financial assistance.

We connect your patients with acquired/immune-mediated thrombotic thrombocytopenic purpura (aTTP/iTTP) to a team dedicated to supporting them through every step of treatment with CABLIVI—from hospital to home. This includes triaging the prescription to the patient's specialty pharmacy and assisting with medication shipments, providing patients with supplemental injection training, supporting your patients with claims and reimbursements, and more.

Our support

Affording CABLIVI

No matter your patient's situation, we are committed to helping them access and afford CABLIVI. The HemAssist team will verify your patient's insurance coverage and determine what financial assistance programs they may be eligible for.

Starting treatment

The HemAssist team can help your patient get started with CABLIVI. This includes supplemental one-on-one injection training.

Ongoing support

Our team provides support and guidance to your patient throughout the CABLIVI journey. This includes helping patients stay on their treatment schedule and providing aTTP/iTTP education.

Financial assistance

HemAssist works directly with your patients to help identify programs they may be eligible for.

Copay Assistance Program*

HemAssist may be able to help eligible patients gain access to CABLIVI for as little as $0.

Enroll now

Patient Assistance Program†

HemAssist’s Patient Assistance Program may be available to help eligible uninsured and underinsured patients.

Explore enrollment options

^{* Not valid for CABLIVI prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DoD, TRICARE®, or similar federal or state programs including any state pharmaceutical assistance programs. Not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Copay Program at any time without notice. Savings may vary depending on the patient’s out-of-pocket costs. Upon registration, the patient will receive all program details. Approval is not guaranteed. Sanofi reserves the right to modify or discontinue the programs at any time. Terms and conditions apply.}

^{† Claims for free products dispensed through HemAssist’s Patient Assistance Program may be available to help eligible uninsured and underinsured patients. Assistance Program shall not be submitted to any third-party payer, public or private (e.g. private insurance, Medicaid, Medicare, VA, DoD, TRICARE®, or similar federal or state programs) for reimbursement. All Programs not valid where prohibited by law. Sanofi reserves the right to modify or terminate the Programs at any time without notice. Program details provided upon registration.}

Meet your team

HemAssist works directly with your patients to help identify programs they may be eligible for.

HemAssist team member sitting at a desk with a headset

Clinical Educator (CE)

CEs can answer questions about aTTP/iTTP and CABLIVI and can provide helpful support to your patients including CABLIVI education, treatment tips, and supplemental injection training.

Portrayal of a smiling man sitting at a desk wearing a headset

Case Managers

Case Managers provide you with personalized insurance investigations and answer questions about financial assistance options for eligible patients.

Portrayal of an woman in an office speaking into a headset

Field Reimbursement Managers (FRM)

Our FRMs can help you navigate insurance coverage and provide reimbursement education and solutions.

Ready to enroll a patient in HemAssist?

It takes just a few steps. Enroll online or download and fax an enrollment form.

Explore enrollment options

INDICATIONS

CABLIVI (caplacizumab-yhdp) is indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

CABLIVI is contraindicated in patients with a previous severe hypersensitivity reaction to caplacizumab-yhdp or to any of its excipients. Hypersensitivity reactions have included urticaria.

WARNINGS AND PRECAUTIONS:

Hemorrhage:

CABLIVI increases the risk of bleeding. In clinical studies, severe bleeding adverse reactions of epistaxis, gingival bleeding, upper gastrointestinal hemorrhage, and metrorrhagia were each reported in 1% of subjects. Overall, bleeding events occurred in approximately 58% of patients on CABLIVI versus 43% of patients on placebo.
In the postmarketing setting cases of life-threatening and fatal bleeding were reported in patients receiving CABLIVI.
The risk of bleeding is increased in patients with underlying coagulopathies (e.g. hemophilia, other coagulation factor deficiencies). It is also increased with concomitant use of CABLIVI with drugs affecting hemostasis and coagulation.
Avoid concomitant use of CABLIVI with antiplatelet agents or anticoagulants. If clinically significant bleeding occurs, interrupt use of CABLIVI. Von Willebrand factor concentrate may be administered to rapidly correct hemostasis. If CABLIVI is restarted, monitor closely for signs of bleeding.
Withhold CABLIVI for 7 days prior to elective surgery, dental procedures or other invasive interventions. If emergency surgery is needed, the use of von Willebrand factor concentrate may be considered to correct hemostasis. After the risk of surgical bleeding has resolved, and CABLIVI is resumed, monitor closely for signs of bleeding.

ADVERSE REACTIONS:

The most common adverse reactions (>15% of patients) were epistaxis (29%), headache (21%) and gingival bleeding (16%).

CONCOMITANT USE OF ANTICOAGULANTS OR ANTIPLATELET AGENTS:

Concomitant use of CABLIVI with any anticoagulant or antiplatelet agent may increase the risk of bleeding. Avoid concomitant use when possible. Assess and monitor closely for bleeding with concomitant use.

PREGNANCY:

There are no available data on CABLIVI use in pregnant women to inform a drug associated risk of major birth defects and miscarriage.

Fetal/neonatal adverse reactions: CABLIVI may increase the risk of bleeding in the fetus and neonate. Monitor neonates for bleeding.
Maternal adverse reactions: All patients receiving CABLIVI, including pregnant women, are at risk for bleeding. Pregnant women receiving CABLIVI should be carefully monitored for evidence of excessive bleeding.

Please see full Prescribing Information
Instructions For Use
Sharps Medical Waste Disposal (PDF)
Learn more about Sanofi’s commitment to fighting counterfeit drugs

Patient support for CABLIVI®

Getting started with CABLIVI

Our support

Affording CABLIVI

Starting treatment

Ongoing support

Financial assistance

Copay Assistance Program*

Patient Assistance Program†

Meet your team

Clinical Educator (CE)

Case Managers

Field Reimbursement Managers (FRM)

Ready to enroll a patient in HemAssist?

INDICATIONS

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS:

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

CONCOMITANT USE OF ANTICOAGULANTS OR ANTIPLATELET AGENTS:

PREGNANCY:

INDICATIONS

IMPORTANT SAFETY INFORMATION

Patient support for CABLIVI^®